Consistently, the high expression of BCL9L in tumor tissues was correlated with a poorer prognosis of patients with melanoma, breast cancer, and other cancer types such as pancreatic cancer, lung cancer, and liver cancer (Figs 6F and EV5J). Here, BCL9L is linked to melanoma.